Literature DB >> 17356126

AT1 receptor blockade prevents interstitial and glomerular apoptosis but not fibrosis in pigs with neonatal induced partial unilateral ureteral obstruction.

Anni Eskild-Jensen1, Lene Fogt Paulsen, Lise Wogensen, Ping Olesen, Lea Pedersen, Jørgen Frøkiaer, Jens Randel Nyengaard.   

Abstract

Obstruction-induced fibrosis is a leading cause of end-stage renal failure in children. The pathophysiological mechanisms may involve apoptosis and the renin-angiotensin system. We studied apoptosis and fibrosis in a well-established neonatal pig model with unilateral partial ureteral obstruction (PUUO) induced during ongoing nephrogenesis in 2-day-old piglets. The role of angiotensin II (ANG II) was studied using the AT(1) receptor blocker CV-11974 (0.12 mg/h candesartan from age 23 to 30 days). At day 30 the kidneys were perfusion fixed and fibrosis, apoptosis, and tubular lengths were quantitated using stereological methods, picro Sirius red staining, and immunohistochemical techniques identifying activated caspase 3, aquaporin-2 (AQP2), and von Willebrand factor. The collagen content was assessed by hydroxyproline density. Neonatal induced PUUO increased interstitial and glomerular cell apoptosis and fibrosis. At this stage, PUUO did not increase tubular cell apoptosis or decrease tubular length and cell number. AT(1) receptor blockade prevented the PUUO-induced interstitial and glomerular cell apoptosis but did not attenuate fibrosis. In conclusion, AT(1) receptor blockade after the end of nephrogenesis may prevent interstitial and glomerular cell apoptosis but not fibrosis, suggesting that pathways not involving AT(1) receptor stimulation contribute to neonatal obstruction-induced fibrosis or that prevention of interstitial cell apoptosis counteracts a potential antifibrotic effect of AT(1) receptor blockade in this pig model of congenital obstructive nephropathy. Our results demonstrate that ANG II plays a role in PUUO-induced glomerular cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17356126     DOI: 10.1152/ajprenal.00479.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  6 in total

Review 1.  Congenital ureteropelvic junction obstruction: human disease and animal models.

Authors:  Julie Klein; Julien Gonzalez; Mathieu Miravete; Cécile Caubet; Rana Chaaya; Stéphane Decramer; Flavio Bandin; Jean-Loup Bascands; Bénédicte Buffin-Meyer; Joost P Schanstra
Journal:  Int J Exp Pathol       Date:  2010-07-30       Impact factor: 1.925

Review 2.  Unilateral ureteral obstruction: beyond obstruction.

Authors:  Alvaro C Ucero; Alberto Benito-Martin; Maria C Izquierdo; Maria D Sanchez-Niño; Ana B Sanz; Adrian M Ramos; Sergio Berzal; Marta Ruiz-Ortega; Jesus Egido; Alberto Ortiz
Journal:  Int Urol Nephrol       Date:  2013-09-27       Impact factor: 2.370

3.  Age-dependent renal expression of acid-base transporters in neonatal ureter obstruction.

Authors:  Guixian Wang; Sukru Oguzkan Topcu; Troels Ring; Jianguo Wen; Jens Christian Djurhuus; Tae-Hwan Kwon; Søren Nielsen; Jørgen Frøkiaer
Journal:  Pediatr Nephrol       Date:  2009-06-03       Impact factor: 3.714

4.  Effect of unilateral ureteral obstruction and anti-angiotensin II treatment on renal tubule and interstitial cell apoptosis in rats.

Authors:  Nikola Radović; Snjezan Cuzić; Mladen Knotek
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

5.  Changes of renal AT1/AT2 receptors and structures in ovine fetuses following exposure to long-term hypoxia.

Authors:  Caiping Mao; Jianquan Hou; Jianyi Ge; Yali Hu; Yang Ding; Yun Zhou; Huiying Zhang; Zhice Xu; Lubo Zhang
Journal:  Am J Nephrol       Date:  2009-11-18       Impact factor: 3.754

6.  Inhibition of IL-1β by Aliskiren Improved Renal AQP2 Expression and Urinary Concentration Defect in Ureteral Obstruction and Release.

Authors:  Shan Hu; Haixia Xie; Renfei Luo; Pinning Feng; Qiaojuan Liu; Mengke Han; Yonglun Kong; Xuenong Zou; Weidong Wang; Chunling Li
Journal:  Front Physiol       Date:  2019-09-13       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.